Wilson'S Disease Copper Dysregulation Mechanistic Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Wilson's disease copper dysregulation pathway describes the cascade from ATP7B gene mutations to copper accumulation in the liver and brain, leading to hepatic and neurological manifestations. This pathway provides a model for understanding copper homeostasis in neurodegeneration.
The ATP7B gene encodes a copper-transporting P-type ATPase essential for:
| Stage | Normal Function | Wilson's Disease Defect |
|---|---|---|
| Intestinal absorption | Copper absorbed via CTR1 | Normal absorption |
| Hepatic uptake | Copper incorporated into ceruloplasmin | Impaired incorporation |
| Biliary excretion | ATP7B pumps copper into bile | Lost function |
| Blood transport | 95% copper bound to ceruloplasmin | 50% as free copper |
Hepatic Pathogenesis:
Neurological Pathogenesis:
| Gene/Protein | Function | Role in Wilson's |
|---|---|---|
| ATP7B | Copper-transporting ATPase | Mutations cause defective transport |
| CTR1 (SLC31A1) | Copper transporter | Increased expression |
| ATOX1 | Copper chaperone | May be compensatory |
| ATP7A | Similar ATPase | Cannot compensate fully |
| Ceruloplasmin | Major copper carrier | Reduced functional form |
| Metallothionein | Copper-binding protein | May be upregulated |
Wilson's disease provides insights into copper's role in neurodegeneration:
| Drug | Mechanism | Efficacy |
|---|---|---|
| Penicillamine | Binds and promotes copper excretion | Good but can worsen neurologically |
| Trientine | Alternative chelator | Better tolerated |
| Tetrathiomolybdate | Prevents copper absorption | Investigational |
The study of Wilson'S Disease Copper Dysregulation Mechanistic Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain. 1912;34(4):295-509. PMID:13186734
Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-142. PMID:12955875
Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore). 1992;71(3):139-164. PMID:1315937
Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089-2111. PMID:18506894
Gitlin JD. Wilson disease. Gastroenterology. 2003;125(6):1868-1877. PMID:14724838
Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis. 2004;8(4):787-805. PMID:15566360
Lutsenko S, Bhattacharjee A, Hubbard AE. Copper handling machinery: molecular basis of copper homeostasis. Metallomics. 2010;2(9):596-608. PMID:21072379
Huster D. Wilson disease. Best Pract Res Clin Gastroenterol. 2010;24(4):531-539. PMID:20833347
Loudianos G, Gitlin JD. Wilson's disease. Semin Liver Dis. 2000;20(3):353-364. PMID:11048204
Ferenci P. Wilson's disease. Clin Gastroenterol Hepatol. 2005;3(7):621-628. PMID:16206499
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%